Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	873.72B
Revenue (ttm)	228.62B
Net Income (ttm)	16.95B
Shares Out	6.66M
EPS (ttm)	2,377.00
PE Ratio	55.20
Forward PE	19.57
Dividend	1,100.00 (0.84%)
Ex-Dividend Date	Sep 27, 2024

Volume	24,638
Average Volume	49,167
Open	130,500
Previous Close	130,100
Day's Range	127,500 - 131,200
52-Week Range	112,100 - 218,000
Beta	0.43
RSI	55.21
Earnings Date	Mar 24, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 721
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 16.95 billion, an increase of 73.81%.